InMed Pharmaceuticals to Merge with Mentari Therapeutics in All-Stock Deal, Securing $290M Private Placement

summarizeSummary

InMed Pharmaceuticals is merging with privately-held Mentari Therapeutics in an all-stock transaction, which includes a $290 million private placement, providing a new pipeline and significant funding for the combined entity.

check_boxKey Events

• Definitive Merger Agreement

  InMed Pharmaceuticals Inc. has entered into a definitive merger agreement to acquire Mentari Therapeutics, Inc. in an all-stock transaction. The combined company will operate as Mentari Therapeutics, Inc. and trade on Nasdaq under a new ticker symbol.

• Significant Private Placement

  A concurrent, oversubscribed private placement of US$290 million into Mentari is expected to close immediately prior to the merger. This financing is projected to fund the combined company's operations through 2028.

• Shareholder Ownership and Valuation

  Pre-merger InMed shareholders are expected to own approximately 1.51% of the combined company, which is anticipated to have a pro forma equity value of approximately US$421.4 million. Mentari holders will own ~29.66%, and new investors from the private placement will own ~68.82%.

• Contingent Value Rights for Legacy Assets

  InMed shareholders of record prior to closing will receive Contingent Value Rights (CVRs), entitling them to 90% of net proceeds, if any, from the disposition of InMed's pre-merger legacy assets.

auto_awesomeAnalysis

This definitive merger agreement with Mentari Therapeutics is a transformative event for InMed Pharmaceuticals, which was previously facing substantial going concern doubts and Nasdaq delisting risks. The transaction includes a significant $290 million private placement, providing the combined company with a cash runway through 2028. While existing InMed shareholders will be heavily diluted, owning approximately 1.51% of the combined entity, they gain a stake in a much larger, well-funded biotechnology company with a new migraine prevention pipeline. This deal effectively provides a lifeline and a new strategic direction, addressing critical financial and operational challenges.